UPDATE: Jefferies Cuts PT to $15 on Rigel Pharmaceuticals on Disappointing Fostamatinib Results
Jefferies reiterated its Buy rating on Rigel Pharmaceuticals (NASDAQ: RIGL) but lowered its price target from $21 to $15.
Jefferies noted, "RIGL announced OSKIRA-4 results in which fostamatinib monotherapy failed to show non-inferiority to Humira. In a separate analysis, higher dose regimens of fostamatinib showed superiority against placebo. With $3 in year-end cash and $2 in cash approval milestones if fostamatanib can be approved, we believe the selloff reflects an overly negative Street view on fostamatinib prospects and would be a buyer."
Rigel Pharmaceuticals closed at $8.43 on Wednesday.
Latest Ratings for RIGL
|Aug 2016||BMO Capital||Maintains||Outperform|
|Aug 2016||BMO Capital||Initiates Coverage on||Outperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.